Thoughts on Healthcare Markets & Technology

Thoughts on Healthcare Markets & Technology

How AI Could Change the Two Billion Dollar Drug Problem: Eroom's Law, Clinical Trial Economics, and Formation Bio's Six Hundred Million Dollar Bet on Faster, Cheaper Drug Development

Nov 22, 2026
∙ Paid

🎧 Podcast episode for paid subscribers only. Also available on Apple Podcasts and Spotify.

Thoughts on Healthcare Markets & Technology
How AI Could Change the Two Billion Dollar Drug Problem: Eroom's Law, Clinical Trial Economics, and Formation Bio's Six Hundred Million Dollar Bet on Faster, Cheaper Drug Development
The two billion dollar drug development cost gets quoted like a fixed price tag. It is not. It is several different numbers depending on what you count, and AI’s ability to change it depends entirely on which number you mean. A thread…
Listen now
4 minutes ago

To listen to paid episodes in Apple or Spotify, link your Substack subscription via the show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).

Table of contents

The two billion dollar number needs an accountant

Eroom’s Law survives better tools

Where AI has earned some credit

Clinical trials are where the spreadsheet meets a person

Formation Bio is buying development capacity

The financing structure deserves its own diligence

What investors should actually measure

Cheaper development could change which diseases get drugs

Thoughts on Healthcare Markets & Technology is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

Abstract

AI can generate plausible molecules much faster than the pharmaceutical industry can establish whether those molecules deserve to become medicines. That mismatch explains both the excitement around computational discovery and the growing interest in companies that finance and operate clinical development. Evidence already supports gains in molecular modeling, patient screening, and certain measurement tasks. Evidence for a durable improvement in approval rates is much less mature. Formation Bio’s six hundred million dollar Drug Development Accelerator Fund offers a useful way to examine the business opportunity: acquire or in-license clinical assets, share operating infrastructure, and finance programs through meaningful readouts. The investment case depends on better decisions, lower development costs, and disciplined ownership economics. A faster molecular suggestion box will not get the whole job done.

User's avatar

Continue reading this post for free, courtesy of Thoughts on Healthcare.

Or purchase a paid subscription.
© 2026 Healthcare Markets & Technology · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for writing, podcasting, and media founders.